183 related articles for article (PubMed ID: 23682075)
1. Effect of zileuton and celecoxib on urinary LTE4 and PGE-M levels in smokers.
Mohebati A; Milne GL; Zhou XK; Duffield-Lillico AJ; Boyle JO; Knutson A; Bosworth BP; Kingsley PJ; Marnett LJ; Brown PH; Akpa EG; Szabo E; Dannenberg AJ
Cancer Prev Res (Phila); 2013 Jul; 6(7):646-55. PubMed ID: 23682075
[TBL] [Abstract][Full Text] [Related]
2. Levels of prostaglandin E metabolite and leukotriene E(4) are increased in the urine of smokers: evidence that celecoxib shunts arachidonic acid into the 5-lipoxygenase pathway.
Duffield-Lillico AJ; Boyle JO; Zhou XK; Ghosh A; Butala GS; Subbaramaiah K; Newman RA; Morrow JD; Milne GL; Dannenberg AJ
Cancer Prev Res (Phila); 2009 Apr; 2(4):322-9. PubMed ID: 19336727
[TBL] [Abstract][Full Text] [Related]
3. Overexpression of 5-lipoxygenase and cyclooxygenase 2 in hamster and human oral cancer and chemopreventive effects of zileuton and celecoxib.
Li N; Sood S; Wang S; Fang M; Wang P; Sun Z; Yang CS; Chen X
Clin Cancer Res; 2005 Mar; 11(5):2089-96. PubMed ID: 15756036
[TBL] [Abstract][Full Text] [Related]
4. Use of a balanced dual cyclooxygenase-1/2 and 5-lypoxygenase inhibitor in experimental colitis.
Pallio G; Bitto A; Pizzino G; Galfo F; Irrera N; Minutoli L; Arcoraci V; Squadrito G; Macrì A; Squadrito F; Altavilla D
Eur J Pharmacol; 2016 Oct; 789():152-162. PubMed ID: 27450484
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of 5-lipoxygenase in rat and human esophageal adenocarcinoma and inhibitory effects of zileuton and celecoxib on carcinogenesis.
Chen X; Wang S; Wu N; Sood S; Wang P; Jin Z; Beer DG; Giordano TJ; Lin Y; Shih WC; Lubet RA; Yang CS
Clin Cancer Res; 2004 Oct; 10(19):6703-9. PubMed ID: 15475461
[TBL] [Abstract][Full Text] [Related]
6. Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203.
Edelman MJ; Watson D; Wang X; Morrison C; Kratzke RA; Jewell S; Hodgson L; Mauer AM; Gajra A; Masters GA; Bedor M; Vokes EE; Green MJ
J Clin Oncol; 2008 Feb; 26(6):848-55. PubMed ID: 18281656
[TBL] [Abstract][Full Text] [Related]
7. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin.
Israel E; Fischer AR; Rosenberg MA; Lilly CM; Callery JC; Shapiro J; Cohn J; Rubin P; Drazen JM
Am Rev Respir Dis; 1993 Dec; 148(6 Pt 1):1447-51. PubMed ID: 8256883
[TBL] [Abstract][Full Text] [Related]
8. Effects of zileuton and montelukast in mouse experimental spinal cord injury.
Genovese T; Rossi A; Mazzon E; Di Paola R; Muià C; Caminiti R; Bramanti P; Sautebin L; Cuzzocrea S
Br J Pharmacol; 2008 Feb; 153(3):568-82. PubMed ID: 18059327
[TBL] [Abstract][Full Text] [Related]
9. Development of a highly sensitive liquid chromatography-mass spectrometry method to quantify plasma leukotriene E
Löfgren L; Forsberg GB; Davidsson P; Eketjäll S; Whatling C
Prostaglandins Other Lipid Mediat; 2020 Oct; 150():106463. PubMed ID: 32450304
[TBL] [Abstract][Full Text] [Related]
10. The effects of a 5-lipoxygenase inhibitor on acute mountain sickness and urinary leukotriene e4 after ascent to high altitude.
Grissom CK; Richer LD; Elstad MR
Chest; 2005 Feb; 127(2):565-70. PubMed ID: 15705997
[TBL] [Abstract][Full Text] [Related]
11. Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel.
Csiki I; Morrow JD; Sandler A; Shyr Y; Oates J; Williams MK; Dang T; Carbone DP; Johnson DH
Clin Cancer Res; 2005 Sep; 11(18):6634-40. PubMed ID: 16166442
[TBL] [Abstract][Full Text] [Related]
12. The cardioprotective effects of zileuton, a 5-lipoxygenase inhibitor, are mediated by COX-2 via activation of PKC delta.
Kwak HJ; Park KM; Choi HE; Lim HJ; Park JH; Park HY
Cell Signal; 2010 Jan; 22(1):80-7. PubMed ID: 19781629
[TBL] [Abstract][Full Text] [Related]
13. Celecoxib inhibits 5-lipoxygenase.
Maier TJ; Tausch L; Hoernig M; Coste O; Schmidt R; Angioni C; Metzner J; Groesch S; Pergola C; Steinhilber D; Werz O; Geisslinger G
Biochem Pharmacol; 2008 Oct; 76(7):862-72. PubMed ID: 18692027
[TBL] [Abstract][Full Text] [Related]
14. Insights into IgE-mediated lung inflammation derived from a study employing a 5-lipoxygenase inhibitor.
Kane GC; Tollino M; Pollice M; Kim CJ; Cohn J; Murray JJ; Dworski R; Sheller J; Fish JE; Peters SP
Prostaglandins; 1995 Jul; 50(1):1-18. PubMed ID: 8588068
[TBL] [Abstract][Full Text] [Related]
15. Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis.
Dovizio M; Tacconelli S; Ricciotti E; Bruno A; Maier TJ; Anzellotti P; Di Francesco L; Sala P; Signoroni S; Bertario L; Dixon DA; Lawson JA; Steinhilber D; FitzGerald GA; Patrignani P
J Pharmacol Exp Ther; 2012 Apr; 341(1):242-50. PubMed ID: 22262921
[TBL] [Abstract][Full Text] [Related]
16. The 5-lipoxygenase inhibitor, zileuton, suppresses prostaglandin biosynthesis by inhibition of arachidonic acid release in macrophages.
Rossi A; Pergola C; Koeberle A; Hoffmann M; Dehm F; Bramanti P; Cuzzocrea S; Werz O; Sautebin L
Br J Pharmacol; 2010 Oct; 161(3):555-70. PubMed ID: 20880396
[TBL] [Abstract][Full Text] [Related]
17. Zileuton, 5-lipoxygenase inhibitor, acts as a chemopreventive agent in intestinal polyposis, by modulating polyp and systemic inflammation.
Gounaris E; Heiferman MJ; Heiferman JR; Shrivastav M; Vitello D; Blatner NR; Knab LM; Phillips JD; Cheon EC; Grippo PJ; Khazaie K; Munshi HG; Bentrem DJ
PLoS One; 2015; 10(3):e0121402. PubMed ID: 25747113
[TBL] [Abstract][Full Text] [Related]
18. The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma.
Israel E; Rubin P; Kemp JP; Grossman J; Pierson W; Siegel SC; Tinkelman D; Murray JJ; Busse W; Segal AT; Fish J; Kaiser HB; Ledford D; Wenzel S; Rosenthal R; Cohn J; Lanni C; Pearlman H; Karahalios P; Drazen JM
Ann Intern Med; 1993 Dec; 119(11):1059-66. PubMed ID: 8239223
[TBL] [Abstract][Full Text] [Related]
19. Elevated levels of urinary prostaglandin e metabolite indicate a poor prognosis in ever smoker head and neck squamous cell carcinoma patients.
Kekatpure VD; Boyle JO; Zhou XK; Duffield-Lillico AJ; Gross ND; Lee NY; Subbaramaiah K; Morrow JD; Milne G; Lippman SM; Dannenberg AJ
Cancer Prev Res (Phila); 2009 Nov; 2(11):957-65. PubMed ID: 19843689
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of zileuton, a novel selective 5-lipoxygenase inhibitor, in patients with systemic lupus erythematosus.
Hackshaw KV; Shi Y; Brandwein SR; Jones K; Westcott JY
J Rheumatol; 1995 Mar; 22(3):462-8. PubMed ID: 7783062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
